



FOR IMMEDIATE RELEASE

Media

Racquel White

Media@Labcorp.com

Investors

Nickolo Russo

Investor@Labcorp.com

Labcorp Announces Definitive Agreement to Acquire Millennium Health

Acquisition aims to expand toxicology testing access nationwide and provide clinical insights to support patients living with chronic pain, substance use disorders and mental health challenges

BURLINGTON, N.C., Oct. 23, 2026 – [Labcorp](#) (NYSE: LH), a global leader in innovative and comprehensive laboratory services, and Millennium Health, an accredited specialty laboratory with more than 15 years of experience in drug testing and surveillance, today announced that they have entered into a definitive agreement for Labcorp to acquire Millennium Health.

Millennium Health provides critical insights into patients' recent use of prescription medications and/or illicit drugs, helping clinicians more effectively monitor and treat individuals living with chronic pain, substance use disorders, mental health conditions and other health needs.

Upon integration, patients, clinicians and Millennium customers are expected to benefit from Labcorp's extensive test menu, patient service center (PSC) network of convenient locations across the U.S. and leading digital solutions to assist with test ordering and result delivery.

"By combining Labcorp's national scale, scientific leadership and digital capabilities with Millennium Health's specialized toxicology testing capabilities and unique drug surveillance tools, we have an opportunity to make a greater impact on people living with chronic pain, mental health conditions and substance use disorders," said Andrea Throop, Ph.D., Head of Toxicology at Labcorp. "We are committed to building upon Millennium's strong reputation and broadening access to high-quality toxicology services for providers and their patients."

"I am incredibly proud of what our team has been able to accomplish at Millennium Health and am very excited about what the next chapter holds," said Millennium Health CEO Scott Walton. "We are committed to our mission of helping customers improve patient care and avoid tragedy, and we are excited about how this acquisition by Labcorp will strengthen our ability to fulfill this role in communities across the country."

The transaction is subject to applicable regulatory approvals and customary closing conditions. Financial terms were not disclosed.

Hogan Lovells Cadwalader served as legal counsel for Labcorp, and Blank Rome served as legal counsel for Millenium Health.

About Labcorp

Labcorp (NYSE: LH) is a global leader of innovative and comprehensive laboratory services that helps doctors, hospitals, pharmaceutical companies, researchers and patients make clear and confident decisions. We provide insights and advance science to improve health and improve lives through our unparalleled diagnostics and drug development laboratory capabilities. The company's nearly 71,000 employees serve clients in approximately 100 countries, provided support for more than 85% of the new drugs and therapeutic products approved by the FDA in 2025 and performed more than 750 million tests for patients around the world. Learn more at www.labcorp.com.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements, including, but not limited to, statements with respect to the anticipated benefits to physicians, patients and customers of the proposed transaction between Millennium Health and Labcorp, including broader access to toxicology services, Labcorp's extensive test menu and patient service center network and digital solutions to support test ordering and result delivery, as well as how the transaction will further support Labcorp's business strategies.

Each of the forward-looking statements is subject to change based on various important factors, many of which are beyond Labcorp's control. These factors, in some cases, have affected and in the future (together with other factors) could affect Labcorp's ability to implement its business strategy, and actual results could differ materially from those suggested by these forward-looking statements. As a result, readers are cautioned not to place undue reliance on any of the forward-looking statements.

Labcorp has no obligation to provide any updates to these forward-looking statements even if its expectations change. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. Further information on potential factors, risks and uncertainties that could affect operating and financial results is included in Labcorp's most recent Annual Report on Form 10-K under the heading RISK FACTORS and in subsequent quarterly reports on Form 10-Q and its other filings with the SEC. The information in this press release should be read in conjunction with a review of Labcorp's filings with the SEC including the information in its most recent Annual Report on Form 10-K under the heading "MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS".

###